understand your treatment and live a healthy...

Understand Your Treatment...and Live a Healthy Life!

Oral antidiabetics

Class Drugs Brand name(non-exhaustive list)

Commercialpresentation

Risk ofhypoglycemia

Biguanides Metformin Glucophage

500 mg 850 mg

No

Biguanides Extended releasemetformin Glumetza

500 mg 1000 mg

No

Alpha-glucosidaseinhibitors Acarbose Glucobay

50 mg 100 mg

No

Dipeptidylpeptidase-4 inhibitors

(incretin pathway)Alogliptin Nesina

6.25 mg 12.5 mg 25 mg

No


and biguanidesAlogliptin

and metformin Kazano12.5/500 mg 12.5/850 mg

12.5/1000 mg

No


(incretin pathway)Linagliptin Trajenta

5 mgNo


and biguanidesLinagliptin

and metformin Jentadueto 2.5/500 mg 2.5/850 mg

2.5/1000 mg

No


(incretin pathway)Saxagliptin Onglyza

2.5 mg 5 mg

No


and biguanidesSaxagliptin

and metformin Komboglyze2.5/500 mg 2.5/850 mg 2.5/1000 mg

No


(incretin pathway)Sitagliptin Januvia

25 mg 50 mg 100 mg

No


and biguanidesSitagliptin

and metformin Janumet 50/500 mg 50/850 mg

50/1000 mg

No


and biguanides

Extended releasesitagliptin and

metforminJanumet XR 50/500 mg 50/1000 mg

100/1000 mg

No

Inhibitors of sodium glucose

co-transporter 2 (SGLT2)Canagliflozin Invokana

100 mg 300 mg

No

Inhibitors of sodium glucose co-transporter 2 (SGLT2) and biguanides Canagliflozin and

metformin Invokamet

50/500 mg 150/500 mg

50/1000 mg 150/1000 mg

No

m

m

m

m

m

m

m

m

m

m

m

m

m

m

Realisation: Centre ambulatoire d’endocrinologie du CHUM.

Isabelle Schmidt, graphist/Isabelle Hamel Blouin, photographer.

* The commercial presentation of the oral drugs is real size.

This documenT was produced Through financial supporT by 6nd edition, 2020/07

Class Drugs Brand name(non-exhaustive list)

Commercialpresentation

Risk ofhypoglycemia

Inhibitors ofsodium glucose

co-transporter 2 (SGLT2)Dapagliflozine Forxiga

5 mg 10 mg

No

Inhibitors of sodium glucose co-transporter 2 (SGLT2) and biguanides

Dapagliflozin and metformin Xigduo

5/850 mg 5/1000 mg

No

Inhibitors ofsodium glucose

co-transporter 2 (SGLT2)Empagliflozin Jardiance

10 mg 25 mg

No

Inhibitors of sodium glucose co-transporter 2 (SGLT2) and biguanides

Empagliflozin and metformin Synjardy

5/500 mg 12.5/500 mg

5/850 mg 12.5/850 mg

5/1000 mg 12.5/1000 mg

No

Inhibitors of sodium glucose co-transporter 2 (SGLT2) and dipeptidyl peptidase-4 inhibitors

Empagliflozin and linagliptin Glyxambi

10/5 mg 25/5 mg

No

Thiazolidinediones Pioglitazone Actos15 mg 30 mg 45 mg

No

Thiazolidinediones Rosiglitazone Avandia2 mg 4 mg 8 mg

No

Thiazolidinedionesand biguanides Rosiglitazone

and metformin Avandamet2/500 mg 2/1000 mg

4/500 mg 4/1000 mg

No

Meglitinides(insulin secretagogues) Repaglinide GlucoNorm

0.5 mg 1 mg 2 mg

Yes

Sulfonylureas (insulin secretagogues) Glimepiride Amaryl

1 mg 2 mg 4 mg

Yes

Sulfonylureas (insulin secretagogues) Glyburide Diaßeta

2.5 mg 5 mg

Yes

Sulfonylureas (insulin secretagogues) Gliclazide Diamicron

80 mg

Yes

Sulfonylureas (insulin secretagogues)

Gliclazidemodified release Diamicron MR

30 mg 60 mg

Yes




m

m

m

m

m

m

m

m

m

m

m

m

m

* The commercial presentation of the oral drugs is real size.


Oral antidiabetics




Injectable antidiabetics other than insulin


Others :

GLP-1 receptor agonists do not cause hypoglycemia unless used with insulin or an insulin secretagogue.

Class Drugs Brand nameCommercialpresentation

(prefill pen)

Frequency of administration

Glucagon-like peptide-1 (GLP-1) receptor agonists

Liraglutide Victoza 6 mg/mL (3 mL)No of doses/pen:

30 X 0,6 mg; 20 X 1,2 mg; 10 X 1,8 mg

Once a day


Lixisenatide Adlyxine

0,05 mg/mL (3 mL) No of doses/pen: 14 X 10 ug

0,1 mg/mL (3 mL) No of doses/pen: 14 X 20 ug

Once a day


Exenatide Byetta

250 ug/mL (1,2 mL) No of doses/pen: 60 X 5 ug

250 ug/mL (2,4 mL) No of doses/pen: 60 X 10 ug

Twice a day

Glucagon-likepeptide-1 (GLP-1)receptor agonists

long-actingDulaglutide Trulicity

0,75 mg/0,5 mL No of doses/pen: 1 X 0,75 mg

1,5 mg/0,5 mL No of doses/pen: 1 X 1,5 mg

Once weekly


long-acting

Exenatide extended-release

suspensionBydureon 2 mg (0,65 mL after dilution)

No of doses/pen: 1 X 2 mgOnce weekly


long-actingSemaglutide Ozempic

1,34 mg/mL (1,5 mL)No of doses/pen: 8 X 0,25 mg; 4 X 0,5 mg

1,34 mg/mL (3 mL)No of doses/pen: 4 X 1 mg

Once weekly

Combinaison basal insulins and

glucagon-likepeptide-1 (GLP-1) receptor agonists

Insulin glargine + lixisenatide Soliqua 100 units/mL insulin glargine +

33 ug/mL lixisenatide (3 mL)Once a day

Combinaison basal insulins and

glucagon-likepeptide-1 (GLP-1) receptor agonists

Insulin degludec + liraglutide Xultophy 100 units/mL insulin degludec +

3,6 mg/mL liraglutide (3 mL)Once a day

m

m

m

m

m

m

m

m

m

Suggested document: FIT Canada-Forum for Injection Technique Canada - Recommendation for best practice in injection techniques - 3rd edition 2017 - www.fit4diabetes.com

understand your treatment and live a healthy...

Documents